Rare FNIP1 Loss-of-Function Variants Tied to 60% Lower Cardiometabolic Disease Odds in 1-Million-Person Exome Study

The Nature study performed exome-wide association testing for TG:HDL ratio using REGENIE software on 11 cohorts spanning North America, Europe and Asia. Researchers identified 59 genes, with FNIP1 emerging as a key regulator that normally brakes cellular energy expenditure. Carriers of protein-truncating variants, occurring at roughly 1 in 7,000 frequency, showed lower body-fat percentage, reduced hepatic steatosis and approximately 60% lower odds of cardiometabolic disease after adjustment for ancestry and BMI. These associations were driven by direct sequencing rather than imputation, strengthening causal inference for the observed metabolic phenotype.

The TG:HDL ratio served as a scalable proxy for whole-body energy partitioning, correlating with visceral adiposity and insulin resistance measured by imaging and clamp studies in subsets. Prior smaller GWAS had implicated common variants near FNIP1, yet the present work isolates rare, high-impact alleles that produce larger effect sizes, consistent with patterns seen for MC4R and PCSK9. The design remains observational; residual confounding from unmeasured lifestyle factors cannot be excluded despite the large sample.

Future functional studies must test whether FNIP1 haploinsufficiency alters AMPK-mTOR signaling in human adipocytes and hepatocytes. Clinical translation will require prospective cohorts that track incident diabetes and MACE events over at least five years in confirmed carriers versus matched non-carriers.

Next steps include targeted sequencing in underrepresented ancestries and CRISPR-based cellular models to quantify changes in fatty-acid oxidation rates.